Intramuscularly Administered SNAP-TI Nanoparticles Induce Systemic Antigen-Specific Tolerance
Time: 10:00 am
day: Conference Day Two
Details:
- Introducing the SNAP-TI platform and mechanism of action in animal models of Type 1 Diabetes and Multiple Sclerosis
- Discussing the VTP-1000 drug product candidate based on SNAP-TI for celiac disease
